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Abstract
Background: Although FOXO transcription factors may have an anti-angiogenic role, little is known about their
role in tumor angiogenesis. The present study was performed to investigate the correlation between the
constitutive expression of phosphorylated FOXO1 (pFOXO1) and angiogenesis in gastric cancer.
Methods: Immunohistochemistry was performed on tissue array slides containing 272 gastric carcinoma specimens,
and the correlations between the cytoplasmic pFOXO1 expression in gastric cancer cells and CD34-immunopositive
microvessel area (MVA) or the expressions of angiogenesis-related molecules were analyzed. In vitro analyses with
Western blotting and semiquantitative reverse transcription-polymerase chain reaction were performed using the
stable SNU-638 gastric cancer cell line transfected with lentivirus-delivered FOXO1 short hairpin RNA.
Results: The cytoplasmic expression of pFOXO1 in tumor cells was observed in 85% of gastric carcinoma cases,
and was found to be positively associated with higher MVA (P = 0.048). Moreover, pFOXO1 expression was
positively correlated with the expressions of several angiogenesis-related proteins, including hypoxia inducible
factor-1a (HIF-1a, P = 0.003), vessel endothelial growth factor (P = 0.004), phosphorylated protein kinase B (P <
0.001), and nuclear factor-B (P = 0.040). In contrast, the expression of pFOXO1 was not correlated with that of
phosphorylated signal transducer and activator of transcription 3 or b-catenin. In addition, cell culture experiments
showed that FOXO1 suppression increased the mRNA and protein expressions of HIF-1a.
Conclusion: Our results suggest that pFOXO1 expression in cancer cells plays a role in gastric cancer angiogenesis
via mechanisms involving various angiogenesis-related molecules. Animal experiments are needed to confirm the
anti-angiogenic role of FOXO1 in human gastric cancer.
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Background
The FOXO (Forkhead box, class O) is a subfamily of
forkhead transcription factor and consists of FOXO1A
(FKHR: Forkhead in rhabdomyosarcoma, also known as
FOXO1), FOXO3A (FKHR-like 1), MLLT7 (AFX: acute-
lymphocytic-leukaemia-1 fused gene from chromosome
X, also known as FOXO4) and FOXO6 [1]. Phosphory-
lated FOXOs could not exhibit transcriptional activity
because the phosphorylated forms are exported from
the nucleus [2]. FOXOs are now emerging as an impor-
tant family of proteins that are implicated in the regula-
tions of several biological processes, including the stress
resistance, metabolism, cell cycle, apoptosis, and DNA
repair [3]. Thus, dysregulations of these proteins may
ultimately lead to disease such as cancer [4].
Inactivation of FOXOs has been reported in various
cancers, including breast cancer, prostate cancer,
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chronic myelogenous leukemia, glioblastoma, rhabdo-
myosarcoma, and leukemia [5]. Previous studies have
shown that the anti-tumor activity of FOXOs comes
from their pro-apoptotic [6-8] and inhibitory cell cycle
effects [3,9]. Recently, abnormal vascular development
was observed in embryonic FOXO1-deficient mice [10],
and in another study, it was found that FOXO1 and
FOXO3A are critical regulators of endothelial sprout
formation and migration in vitro [11]. Accordingly, it
was suggested that the inactivation of FOXOs might
regulate angiogenesis [12]. However, the role of FOXOs
in tumor angiogenesis has not been investigated.
Gastric cancer is one of the most common cancers,
and the major cause of cancer-related death worldwide
[13]. However, the molecular mechanism underlying
gastric tumor angiogenesis remains unclear. Previously,
it was reported that the phosphorylated inactive form of
FOXO1 (pFOXO1) was constitutively expressed in gas-
tric cancer and that this was clinically significant [14].
To investigate the correlation between pFOXO1 and
angiogenesis in gastric cancer, the present study per-
formed immunohistochemical tissue array analysis using
272 surgically excised human gastric cancer specimens.
Subsequently, we analyzed the correlation between the
expression of pFOXO1 and microvessel area (MVA) or
the expressions of several angiogenesis-related mole-
cules, including hypoxia inducible factor-1a (HIF-1a),
vessel endothelial growth factor (VEGF), phosphorylated
protein kinase B (pAKT), and nuclear factor-B (NF-
B), phosphorylated signal transducer and activator of
transcription 3 (pSTAT3) and b-catenin. In addition, we
performed cell culture experiments after establishing a
stable gastric cancer cell line transfected with lentivirus-
delivered FOXO1 short hairpin RNA (shRNA).
Methods
Patients and Samples
The files of 272 surgically resected gastric cancer cases
examined at the Department of Pathology, Seoul
National University College of Medicine from 1 January
to 30 June 1995 were analyzed. Age, sex, tumor location
and pTNM stage were evaluated by reviewing the medi-
cal records and pathological reports [15]. The mean age
of the patients was 54.8 years, and 93.3% of the patients
had undergone curative resection. The cases enrolled in
this study included 193 advanced and 79 early gastric
carcinomas. According to the UICC criteria, there were
112 cases in stage I, 53 cases in stage II, 63 cases in
stage III, and 44 cases in stage IV. No patient had
received preoperative chemotherapy or radiotherapy.
Glass slides were reviewed to determine histological
type according to the WHO and Lauren’s classification.
his series included 102 intestinal types, 166 diffuse
types, and 4 mixed types. Clinical outcomes were
followed from the date of surgery to either the date of
death or December 1st, 2000, resulting in the follow-up
period ranged from 1 month to 72 months (mean, 51
months). Cases lost to follow up and those resulting in
death from any cause other than gastric cancer were
censored for survival rate analysis. This protocol was
reviewed and approved by the Institutional Review
Board of Seoul National University (Approval No. C-
0511-519-163).
Tissue array methods
Six array blocks obtained from patients with a gastric
cancer were prepared as described previously (Superbio-
chips Laboratories, Seoul, Korea) [16]. Briefly, core tis-
sue biopsies (2 mm in diameter) were taken from
individual paraffin-embedded gastric tumors (donor
blocks) and arranged in the new recipient paraffin
blocks (tissue array block) using a trephine apparatus.
As we have reported previously [16], the staining results
of the different intratumoral areas of gastric carcinomas
in these tissue array blocks showed an excellent agree-
ment. A core was chosen from each case for analysis.
We defined an adequate case as a tumor occupying
more than 10% of the core area. Sections of 4 μm thick-
ness were cut from each tissue array block, deparaffi-
nized, and dehydrated.
Immunohistochemistry
Immunohistochemical staining was performed as
described previously using a streptavidin peroxidase pro-
cedure (avidin-biotin complex method) after antigen
retrieval using an autoclave [17]. Anti-phospho-Ser256-
FOXO1 (1:50) from Cell Signaling Technology (Beverly,
MA, USA) was used as the primary antibody. Other pri-
mary antibodies used were anti-CD34 (1:300, Immuno-
tech, Cedex, France), anti-HIF-1a (donated by JW Park
at SNU, Seoul, Korea), anti-VEGF (1:250, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-phospho-
Ser473-AKT (1:100, New England Biolabs, Beverly, MA,
USA), anti-NF-B p65 (1:50, Santa Cruz Biotechnology),
anti-phospho-Tyr705-STAT3 (1:50, Cell Signaling Tech-
nology) and anti-b-catenin (1:200, Transduction, Lexing-
ton, KY, USA). The results of immunostaining were
evaluated by two pathologists (JHK and MSC), who
were blinded to the origin of the samples. The concor-
dance rates were generally high ranging from 75.7% (
= 0.328, P < 0.001) to 87.5% ( = 0.591, P < 0.001). Dis-
crepancies were resolved by reaching consensus. For sta-
tistical analysis, the results of immunostaining for
proteins were considered positive if immunoreactivity
was seen in ≥ 10% (cytoplasmic pFOXO1, cytoplasmic
VEGF, cytoplasmic and nuclear pAKT, nuclear NF-B
and nuclear b-catenin), ≥ 5% (nuclear HIF-1a) or ≥ 1%
(nuclear pSTAT3) of the neoplastic cells.
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Evaluation of microvessel area (MVA)
Vessel areas immunostained with an anti-CD34 antibody
in gastric cancer specimens were determined as described
previously [17]. Tissue sections were examined by two
independent observers (SYK and JY). Briefly, the three
most highly vascularized areas in areas of tumor sections
were selected under × 100 magnification and photo-
graphs of CD34-immunopositive microvessel vessels in
tumor sections were taken under × 200 magnification
using light microscopy. The cross-sectional areas of
CD34-immunopositive structures (i.e. MVA) were quan-
tified by capturing images, converting them to gray scale
and analyzing CD34-stained areas using NIH Image Ana-
lysis software (version 1.62; National Institute of Health,
Bethesda, MD, USA) after setting one consistent intensity
threshold for all slides. Then, CD34-positive areas were
expressed as pixels squared per high-power field.
Cell culture
A human gastric cancer cell line SNU-638 was obtained
from the Korean Cell Line Bank (Seoul, Korea), cultured
in RPMI-1640 medium (Life Technologies, Grand
Island, NY, USA) containing 10% fetal bovine serum
(Life Technologies), and maintained in a 37°C humidi-
fied incubator containing 95% air and 5% CO2. To
examine the effect of FOXO1 suppression on HIF-1a
expression, cells were incubated under either normoxic
or hypoxic conditions.
Lentivirus-mediated shRNA silencing of FOXO1
FOXO1 shRNA lentiviral particles and non-targeting
shRNA control particles were purchased (Sigma, St
Louis, MO, USA). The sequence of the shRNA targeting
FOXO1 used in the present study is the following:
CCGGGCCTGTTATCAATCTGCTAAACTCGAGTT-
TAGCAGATTGATAACAGGCTTTTTG. The non-tar-
geting shRNA control particles contain 4 basepair
mismatches within the short hairpin sequence to any
known human or mouse gene. The viral infection was
performed by incubating SNU-638 gastric cancer cells
in the culture medium containing lentiviral particles for
12 h in the presence of 5 μg/ml Polybrene (Santa Cruz
Biotechnology). Pooled puromycin (2 μg/ml)-resistant
cells were harvested and stored for further analysis.
Western blotting
Cell lysates were prepared in 100-200 μl of 1 × SDS lysis
buffer [125 mM Tris-HCl (pH 6.8), 4% SDS, 0.004%
bromophenol blue, and 20% glycerol] and then boiled
for 10 min. Protein contents were measured using BCA
Protein Assay Reagent (Pierce, Rockford, IL, USA). Sam-
ples were diluted with 1 × lysis buffer containing 1.28
M b-mercaptoethanol, and equal amounts of protein
were loaded onto 8-12% SDS-polyacrylamide gels.
Proteins were electrophoretically transferred to PVDF or
nitrocellulose membranes, and membranes were then
blocked with 5% nonfat dry milk in PBS/Tween-20
(0.1%, vol/vol) at 4°C overnight. They were then incu-
bated with a primary antibody against FOXO1 (1:1000;
Cell Signaling Technology), HIF-1a (1:1000; donated by
JW Park), or b-actin (1:1000; Sigma) for 2 h. They were
then incubated with a corresponding secondary anti-
body, either horseradish peroxidase-conjugated anti-rab-
bit IgG (1:2000; Zymed, San Francisco, CA, USA) or
anti-mouse IgG (1:2500; Santa Cruz Biotechnology) for
2 h, and enhanced chemiluminescence (ECL) (Amer-
sham Biosciences, Arlington Heights, IL, USA) was used
for the visualization of the immunoreactive proteins.
Equal loading of the protein was confirmed by b-actin.
Semiquantitative reverse transcription-polymerase chain
reaction (SQ RT-PCR)
To quantify mRNA levels, we used a highly sensitive, SQ
RT-PCR method. Total RNAs were isolated using TRI-
ZOL reagent purchased from Invitrogen (Carlsbad, CA,
USA), and 1 μg of RNAs were reverse-transcribed at 48°
C for 30 min. Complementary DNAs were amplified
over 18 PCR cycles (94°C for 30 sec, 52°C for 30 sec,
and 70°C for 30 sec) in a reaction mixture containing 5
mCi (a-32P)dCTP (NEN, Boston, MA, USA). The result-
ing PCR fragments (5 ml) were electrophoresed on a 2%
agarose gel at 100 V in 1 × TAE, and the gels were
dried and autoradiographed. Primer sequences were 5’-
CCCCAGATTCAGGATCAGACA-3’ and 5’-CCAT-




All statistical analyses were conducted using SPSS version
11.0 software (SPSS, Chicago, IL, USA). The significance
of correlation between the expressions of pFOXO1 and
other proteins was determined by the chi-squared test.
MVAs were expressed as means ± S.D. and the relation-
ship between pFOXO1 expression and MVA was analyzed
using the two-tailed Student’s t-test. Survival curves were
estimated using the Kaplan-Meier product-limit method,
and the significance of differences between the survival
curves was determined using the log-rank test. Regarding
the survival curve, the MVA score was considered positive
when the value was higher than the mean value and vice
versa. P < 0.05 was considered significant.
Results
Expressions of pFOXO1 and angiogenesis-related proteins
in gastric cancer specimens
Immunohistochemical staining was used to investigate
the correlation between pFOXO1 expression and
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angiogenesis in gastric cancer. Figure 1 shows represen-
tative immunohistochemical features of proteins in gastric
cancer tissues. pFOXO1 (Figure 1A and 1B) and HIF-1a
(Figure 1E and 1F) were found to be expressed in both the
nuclei and cytoplasm of tumor cells. Regarding pFOXO1
staining, cells showing distinct cytoplasmic staining,
regardless of the presence of nuclear staining, were consid-
ered to express pFOXO1 constitutively, whereas those
with nuclear HIF-1a expression, regardless of the presence
of cytoplasmic staining, were considered to exhibit
activated HIF-1a. Since immunostaining was performed
with an antibody against an inactivated form of FOXO1
(pFOXO1), an increase in pFOXO1 expression was
interpreted as a decrease in FOXO1 activation. Conse-
quently, correlations between pFOXO1 and other pro-
teins are opposite to those between activated FOXO1
and these proteins. Constitutive pFOXO1 expression
was observed in 230 (85%) of the 272 gastric cancer
cases examined.
Association between the expression of pFOXO1 and MVA
MVA is a widely accepted measure of neoangiogenetic
activity in cancer. Mean CD34-positive microvessel
areas were found to be significantly larger in pFOXO1-
positive tumors (Figure 1C) than in pFOXO1-negative











Figure 1 Representative immunohistochemical findings in gastric cancer tissues. A: gastric carcinoma cells showing cytoplasmic pFOXO1A
expression with or without nuclear staining (× 400). B: gastric carcinoma cells without cytoplasmic pFOXO1A expression (× 400). C: a
representative gastric tumor section showing high MVA (× 200). D: a representative gastric tumor section showing low MVA (× 200). E: gastric
carcinoma cells showing nuclear HIF-1a expression with or without cytoplasmic staining (× 400). F: gastric carcinoma cells without nuclear HIF-
1a expression (× 400). G: gastric carcinoma cells showing cytoplasmic VEGF expression (× 400). F: gastric carcinoma cells without cytoplasmic
VEGF expression (× 400).
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pFOXO1 expression and MVA in relation to prognosis
Our analysis of the 272 gastric cancer patients revealed
that those with pFOXO1 expression had a significantly
higher survival rate than those without pFOXO1 expres-
sion (P = 0.004) (Figure 2A). In our analysis of the
combined status of the expression of pFOXO1 and
MVA in relations to prognosis, patients with a
pFOXO1-positive tumor and higher MVA had better
outcome than patients with the other combinations (P
= 0.025) (Figure 2B).
Correlation between the expression of pFOXO1 and the
expression of angiogenic proteins in surgical gastric
cancer samples
To investigate the positive correlation found between
pFOXO1 expression and angiogenesis further, we ana-
lyzed the associations between the expression of
pFOXO1 and the expressions of other potential media-
tors of angiogenesis. Table 2 shows that pFOXO1
expression was positively correlated with the expressions
of the critical angiogenic regulators HIF-1a (P = 0.003)
and VEGF (P = 0.004). Furthermore, pFOXO1 expres-
sion was significantly and positively correlated with the
expressions of other pro-angiogenic molecules, that is,
pAKT (P < 0.001) and NF-B (P < 0.040), but not with
those of pSTAT3 and b-catenin.
Correlations between pFOXO1 expression in tumor cells
and MVA in HIF-1a-positive and HIF-1a-negative tumors
and in VEGF-positive and VEGF-negative tumors
To remove the possible confounding effects of HIF-1a and
VEGF on the relationship between cytoplasmic pFOXO1
Table 1 Correlation between cytoplasmic pFOXO1
expression in tumor cells and MVA in gastric cancer
MVA
Cases Mean ± S.D. S.E. P
pFOXO1
Positive 212 10.77 ± 8.8 0.60347 0.048*
Negative 39 7.87 ± 5.3 0.84711
Abbreviations: MVA, microvessel area; pFOXO1, phosphorylated Forkhead in
rhabdomyosarcoma.
* Considered to be statistically significant.
Figure 2 Kaplan-Meier curves for gastric cancer patient
survival according to immunohistochemical status. A: Patients
with a pFOXO1-positive carcinoma (solid line) showed a more
favorable prognosis than those with a pFOXO1-negative carcinoma
(dotted line) (P = 0.004). B: Patients with a pFOXO1-positive
carcinoma and with higher MVA (solid line) showed the best
outcome (P = 0.025).
Table 2 Correlation between the expression of pFOXO1
and that of angiogenesis-related proteins in tumor cells
in gastric cancer
pFOXO1
Positive (%) Negative (%) P
pFOXO1
HIF-1a
Positive 64 (96) 3 (4) 0.003*
Negative 133 (80) 34 (20)
VEGF
Positive 87 (93) 7 (7) 0.004*
Negative 110 (79) 30 (21)
pAKT
Positive 169 (90) 18 (10) < 0.001*
Negative 28 (60) 19 (40)
NF-B
Positive 38 (95) 2 (5) 0.040*
Negative 159 (82) 35 (18)
pSTAT3
Positive 49 (89) 6 (11) 0.255
Negative 148 (83) 31 (17)
b-catenin
Positive 38 (86) 6 (14) 0.661
Negative 159 (84) 31 (16)
Abbreviations: pFOXO1, phosphorylated Forkhead in rhabdomyosarcoma
(cytoplasmic staining).
HIF-1a, hypoxia inducible factor-1a (nuclear staining); VEGF, vessel endothelial
growth factor (cytoplasmic staining); pAKT, phosphorylated protein kinase B
(cytoplasmic and nuclear staining).
NF-B, nuclear factor-B (nuclear staining); pSTAT3, phosphorylated signal
transducer and activator of transcription 3 (nuclear staining); b-catenin
(nuclear staining).
* Considered to be statistically significant.
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expression and angiogenesis in gastric cancer, we divided
samples into two groups according to the expression of
HIF-1a or VEGF (Table 3). Although pFOXO1 expression
positively correlated with MVA in overall patients (P =
0.048), there was no significant correlation after we
removed the effect of HIF-1a or VEGF expression.
Effect of FOXO1 inhibition on the expression of HIF-1a in
gastric cancer cells in vitro
HIF-1a has been reported to increase gastric tumor
growth and angiogenesis [18]. Thus, we performed cell
culture experiments to further examine the direct rela-
tionship between the expressions of FOXO1 and HIF-
1a. FOXO1 expression was suppressed by transfecting
FOXO1 shRNA into SNU-638 gastric cancer cells, and
subsequently, cells were cultured under normoxic or
hypoxic conditions. Western blot analysis showed that
decreased FOXO1 expression increased HIF-1a protein
expression under hypoxic conditions (Figure 3, upper),
and RT-PCR showed that decreased FOXO1 expression
increased HIF-1a mRNA expression under both nor-
moxic and hypoxic conditions (Figure 3, lower). These
results suggest that FOXO1 inhibits HIF-1a expression
at the transcriptional level.
Discussion
Angiogenesis is a complex, multistep process, which is
tightly controlled by a balance between pro- and anti-
angiogenic factors [19,20]. Although it has been previously
reported that FOXO1 in endothelial cells has an anti-
angiogenic function [10], the correlation between FOXO1
and tumor angiogenesis remains unknown. In the present
study, our results of immunohistochemical tissue array
analysis and in vitro cell culture experiments suggest that
FOXO1 in gastric cancer cells is implicated in gastric
tumor angiogenesis. This is the first report, to the best of
our knowledge, to show a link between FOXO1 activation
in cancer cells and tumor angiogenesis.
Tumor angiogenesis can be investigated in several
ways: (i) by measuring microvessel densities (MVDs) or
microvessel areas (MVAs) in tumor tissues, (ii) by quan-
tifying angiogenic molecules or angiogenic receptors
within tumor tissues, or (iii) by measuring angiogenic
factor levels in serum and urine of cancer patients
[21-25]. In the present study, we evaluated MVAs
(CD34-immunopositive microvessel areas) in gastric
tumor sections and the expressions of several angiogenic
molecules to investigate angiogenesis.
It is known that vessel area is a critical determinant of
blood flow (Poiseuille’s law) [26]. Thus, Stoeltzing et al.
(2004) measured MVA in tissue sections of gastric
Table 3 Correlations between the MVA and pFOXO1
expression in tumor cells in HIF-1a-positive and
HIF-1a-negative tumors and in VEGF-positive and
VEGF-negative tumors
MVA
Cases Mean ± S.D. P
HIF-1 positive
pFOXO1
Positive 61 12.06 ± 10.9 0.336
Negative 3 5.85 ± 9.0
HIF-1 negative
pFOXO1
Positive 130 9.40 ± 7.2 0.332
Negative 33 8.11 ± 5.2
VEGF positive
pFOXO1
Positive 84 10.49 ± 8.2 0.667
Negative 6 9.02 ± 4.3
VEGF negative
pFOXO1
Positive 107 10.79 ± 9.3 0.071
Negative 30 7.56 ± 5.5
Abbreviations: pFOXO1, phosphorylated Forkhead in rhabdomyosarcoma
(cytoplasmic staining); HIF-1a, hypoxia inducible factor-1a (nuclear staining);




































Figure 3 Effect of FOXO1 inhibition on HIF-1a expression
under hypoxic conditions in vitro. SNU-638 gastric cancer cells
were infected with a lentivirus containing a construct, encoding
either FOXO1 shRNA (denoted as shFOXO1) or non-targeting shRNA
(denoted as LVcontrol). Expression levels of HIF-1a and b-actin
proteins were determined by Western blotting (WB) and the mRNA
expressions of HIF-1a and b-actin were determined by SQ RT-PCR
(RT-PCR) after cells were exposed to either normoxia (N) or hypoxia
(H) for 8 h.
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cancer xenografts in nude mice to analyze the functional
vascular network in gastric cancer [26]. Moreover, in
renal cell carcinoma, MVA has been reported to be a
more important prognostic marker than MVD [27].
Thus, in present study, MVA was used to investigate
the association between pFOXO1 expression and angio-
genesis. We found that cytoplasmic pFOXO1 expression
in gastric cancer cells was positively correlated with
MVA (P = 0.048), suggesting that FOXO1 is involved in
gastric tumor angiogenesis.
In several previous studies, MVD has been used to
assess angiogenesis in human gastric cancer specimens
[28-33]. Some of them showed a positive association
between high MVD and reduced survival of gastric can-
cer patients [28-30]. However, Cabuk et al. (2007)
reported that MVD was significantly higher in early-
stage gastric tumors [33]. Thus, the prognostic signifi-
cance of MVD in gastric cancer has been inconsistent.
In the present study, MVA was found to be significantly
higher in early-stage gastric tumors (P < 0.001, data not
shown), which agrees with the results of Cabuk et al.
(2007). Thus, we speculate that the discrepancies
between the results of previous studies [28-30] and the
present study do not necessarily stem from the different
methods used to measure angiogenesis.
A large number of molecules that either activate or
inhibit angiogenesis have been identified. Of these, HIF-
1a and VEGF are recognized to be representative mar-
ker proteins of angiogenesis, and are known to be asso-
ciated with pro-angiogenic phenotypes of numerous
tumors, including gastric carcinoma [26]. Although, in a
previous study, we demonstrated that both pFOXO1
and HIF-1a were constitutively over-expressed in gastric
cancer [14,17], the correlation between these transcrip-
tion factors has not been reported in human cancer. In
the present study, large scale immunohistochemical tis-
sue array analysis was performed, and the cytoplasmic
pFOXO1 expression in tumor cells was found to be
positively correlated with the nuclear expression of HIF-
1a (P = 0.003) and with the cytoplasmic expression of
VEGF (P = 0.004) in gastric cancer specimens. However,
no significant correlation was found between pFOXO1
expression and MVA after adjusting for the confounding
effects of HIF-1a and VEGF. Thus, our results suggest
that the positive relationship between pFOXO1 and
MVA is dependent on a positive correlation between
pFOXO1 and HIF-1a or VEGF.
Recent advances in biology demonstrated that RNAi is
a powerful tool in tumor biology investigations. In the
present study, FOXO1 expression was inhibited by
infecting gastric cancer cells (SNU-638) with a shRNA-
expressing lentivirus. In addition, cell culture experi-
ments under hypoxic conditions showed that FOXO1
suppression increased the expressions of HIF-1a at the
mRNA and protein levels. These findings suggest that
FOXO1 is a signaling molecule upstream of HIF-1a in
the angiogenic pathway in gastric cancer, and that gas-
tric tumor angiogenesis could be inhibited, at least in
part, by FOXO1 activation.
FOXO1 is a major substrate of AKT. Indeed, our data
showed that pFOXO1 expression was closely and posi-
tively correlated with the expression of the active form
of AKT (pAKT, P < 0.001). Since we found previously
that AKT activation induced angiogenesis in gastric can-
cer xenografts [17], our results suggest that AKT/
FOXO1 pathway is involved in angiogenesis in gastric
cancer. Furthermore, we found that pFOXO1 expression
was positively correlated with the nuclear expression of
NF-B (P = 0.040), which is also known to induce
tumor angiogenesis [34]. However, no association was
found between pFOXO1 expression and the expressions
of pSTAT3 and nuclear b-catenin in the present study,
although they have been reported to be involved in
angiogenesis in several cancer types [35,36].
Conclusion
Our results suggest that pFOXO1 in combination with
several pro-angiogenic molecules, could induce the
angiogenic phenotypes of gastric cancer. Further in vivo
animal experiments are needed to confirm these
relationships.
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